PURPOSENeoadjuvant immune checkpoint blockade with nivolumab plus ipilimumab improves overall survival (OS) in non–small cell lung cancer (NSCLC); however, randomized data for resectable lung cancer are limited. We report results from the exploratory …
Immunotherapies, specifically monoclonal antibodies targeting the programmed death–1 and programmed death-ligand 1 axis, have rapidly become integral in the management of most patients with early-stage…
The OncoAlert Newsletter is now out for June 23-29, 2023
Funded by a National Cancer Institute research training grant (1T32CA275764-01A1), the Oncology-focused Postdoctoral Training In Care Delivery and Symptom Science (OPTICS) Training Program at Memorial…
Since the addition of rituximab to CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), major advances in first-line therapy of large B-cell
welcome to our new series on NEW FRAMEWORKS FOR FAST WINS. today we cover my fav lessons from 2024 & what’s next PLUS a fun…
When, where and how the H5N1 bird flu virus may evolve and its capacity to spark a pandemic is hard to predict — in part,…
While the administration of tyrosine-kinase inhibitors (TKIs) in ALK rearranged non-small cell lung cancer (NSCLC) has revolutionized precision medicine, detection of gene rearrangements from liquid…
Since the addition of rituximab to CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), major advances in first-line therapy of large B-cell
With the development of chimeric antigen receptor T-cell therapy and biologicals that engage both malignant B cells and normal T cells, the scene is set…
On the history of fluoride and the new NTP Fluoride and IQ Meta-analysis
